Investing.com - Emerson (NYSE: EMR) reported first quarter EPS of $1.22, $0.18 better than the analyst estimate of $1.04. Revenue for the quarter came in at $4.12B versus the consensus estimate of $3.91B.
Guidance
Emerson sees Q2 2024 EPS of $1.22-$1.26 versus the analyst consensus of $1.25.
Emerson sees FY 2024 EPS of $5.30-$5.45 versus the analyst consensus of $5.26.
Emerson's stock price closed at $104.11. It is up 20.36% in the last 3 months and up 21.07% in the last 12 months.
Emerson saw 5 positive EPS revisions and 6 negative EPS revisions in the last 90 days. See Emerson's stock price’s past reactions to earnings here.
According to InvestingPro, Emerson's Financial Health score is "fair performance".
Check out Emerson's recent earnings performance, and Emerson's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
Should you invest $2,000 in EMR right now?
Before you buy stock in EMR, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is EMR one of them?
Reveal Undervalued Stocks Now